Vitau

Vitau successfully expands its subscription base for chronic illness patients across Mexico, leveraging its insurance reimbursement assistance and efficient express delivery network. This leads to strong customer retention and market share gains from traditional pharmacies, pushing its valuation to $100M+ by 2028, reflecting a significant multiple on growing revenue in a large, underserved TAM.

Vitau maintains steady growth in its niche, acquiring new subscribers but facing persistent competition from both traditional pharmacies enhancing online services and other digital health platforms. Revenue grows moderately, leading to a modest valuation increase to $37.5M by 2028, reflecting incremental market penetration and operational improvements.

Intensified competition from well-funded incumbents like Farmacias del Ahorro and other digital players, coupled with high customer acquisition costs and regulatory hurdles, stifles Vitau's growth. The thin competitive moat prevents significant differentiation, leading to a down round or acquisition at a significantly reduced valuation of $5M, wiping out most common stock value given the preference stack.